Skip to main content
PCRX
NASDAQ Life Sciences

Activist DOMA Perpetual Nominates Directors, Demands CEO Replacement & Formal Sale Process for Pacira BioSciences

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$22.87
Mkt Cap
$924.384M
52W Low
$18.8
52W High
$27.64
52W Position info
22% above low
Off High info
17% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

PCRX sits 22% above its 52-week low of $18.8.

Summary

Activist investor DOMA Perpetual Capital Management, holding a 7.1% stake, has nominated three director candidates and publicly called for the replacement of Pacira BioSciences' CEO and a formal sale of the company.


Key Events · Corporate Governance and Compliance · PCRX

  • Activist Nominates Directors

    DOMA Perpetual Capital Management, a beneficial owner of approximately 7.1% of Pacira's outstanding shares, has nominated three highly qualified candidates for election to the Board of Directors.

  • Demands CEO Replacement

    DOMA asserts that CEO Frank Lee should be replaced immediately and an interim CEO appointed, citing significant stock underperformance and management failures.

  • Calls for Company Sale

    The activist investor urges the Board to immediately engage bankers to proceed with a formal sale process of the company, discontinuing future acquisitions.

  • Criticizes Performance & Compensation

    DOMA highlights Pacira's stock being down 56% over the last decade and 68% over the last five years, alongside consistently missed earnings, lowered guidance, and unsustainable executive compensation.


Analysis · PCRX · Life Sciences

This filing details a significant activist campaign by DOMA Perpetual Capital Management, a 7.1% shareholder, against Pacira BioSciences' current management and board. DOMA is demanding the immediate replacement of CEO Frank Lee and a formal process to sell the company, citing years of severe stock underperformance, missed earnings, and excessive executive compensation. The nomination of three new director candidates signals a proxy fight aimed at fundamentally altering the company's leadership and strategic direction. This event introduces substantial uncertainty and pressure on the company, potentially leading to a major strategic shift or a prolonged governance battle.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PCRX was trading at $22.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $924.4M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PCRX - Latest Insights

PCRX
Nov 17, 2026, 8:50 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $36.49
Real-time Price: $36.49 info
Change: $0 (0%) info
Market Cap: $1.463B info
PCRX
Nov 12, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.46
Real-time Price: $36.49 info
Change: +$0.030 (+0.08%) info
Market Cap: $1.463B info
PCRX
Nov 12, 2026, 4:15 PM EST
Filing Type: SC 14D9/A
Importance Score:
7
Price at Filing: $36.46
Real-time Price: $36.49 info
Change: +$0.030 (+0.08%) info
Market Cap: $1.463B info
PCRX
Nov 05, 2026, 4:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $36.42
Real-time Price: $36.49 info
Change: +$0.070 (+0.19%) info
Market Cap: $1.463B info
PCRX
Nov 05, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.42
Real-time Price: $36.49 info
Change: +$0.070 (+0.19%) info
Market Cap: $1.463B info